Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.

Jianfei Wang,Xiaohong Yu,Shun Wei Zhu,Qing-Ying Chen,Jikui Sun,Yuanfeng Xia,Yang Zhang,Chi-Chung Chan,Jian Li,Shuhui Chen

Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.

2020

Jianfei Wang
Xiaohong Yu
Shun Wei Zhu
Qing-Ying Chen
Jikui Sun
Yuanfeng Xia
Yang Zhang
Chi-Chung Chan
Jian Li
Shuhui Chen

e21663Background: Fusions and rearrangements of NTRK1/2/3 and ROS1 genes are oncogenic drivers in multiple solid malignancies. Drugs targeting tyrosine kinases TrkA/B/C and ROS1, such as larotrecti...

Keywords:

Small molecule
Trk receptor
dual inhibitor
ROS1
Pathology
ROS1 Fusion
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations